EBITDA

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

Lindsay Corp.'s massive irrigation project in MENA isn't just a sale; it's a strategic move in the high-stakes race to solve global food security.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

A new 8MWh energy storage system in Matsusaka showcases how advanced technology is helping Japan balance industrial power with its green energy ambitions.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Beyond the awards, the 2025 TISDC reveals Taiwan's strategy for global creative leadership and how young designers are tackling the world's biggest problems.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.